June 20, 2012 |
One multiple sclerosis expert is applauding Jack Osbourne's decision to deal with his diagnosis in public -- but she doesn't necessarily encourage patients do the same. Even in this day and age of oversharing on social media, revealing one's medical condition could have unforeseen consequences, said clinical psychologist Dr. Rosalind Kalb of the National Multiple Sclerosis Society , where she's vice president of the Professional Resource Center. "I do not advise patients going public until they've gotten all the information they need about the implication of what the illness means ," she told the Los Angeles Times.
CALIFORNIA | LOCAL
February 25, 1998 |
A local chapter of a nationwide health organization will present a six-week seminar starting next month designed to help people and their families cope with multiple sclerosis. The Channel Islands Chapter of the National MS Society is scheduled to begin its course 4:30 p.m. March 4, and the classes will run six consecutive Wednesdays at Goebel Senior Adult Center, 1385 E. Janss Road, in Thousand Oaks.
August 4, 2007 |
Scientists who screened the entire human genome in more than 12,360 people have implicated at least three genes in the incurable nerve disorder multiple sclerosis, and hinted that a dozen more might be involved, according to reports this week in Nature Genetics and the New England Journal of Medicine. Earlier research suggested that two of the genes, IL2R and a gene in the human leukocyte antigen complex, were implicated in MS.
March 27, 2013 |
A new oral medication for multiple sclerosis has won the Food and Drug Administration's marketing approval, and is to become available almost immediately to patients suffering from the debilitating auto-immune disease. Tecfidera is the commercial name for dimethyl fumarate, a capsule that won the FDA's blessing Wednesday as a treatment for relapsing MS, a degenerative brain disorder that can impair mobility, sensation and thinking. In clinical trial evidence submitted to the FDA by Biogen Idec of Weston, Mass., the medication's maker, Tecfidera reduced the proportion of patients who relapsed when compared with a sham medication.
September 22, 2010
A failed anti-rejection drug got a new purpose and a new lease on commercial life Wednesday as the Food and Drug Administration approved the medication fingolimod -- to be marketed as Gilenya -- to slow the progression of disability in multiple sclerosis patients. Gilenya becomes the first MS medication that can be taken daily in pill form, and it joins a small clutch of injectable medications that sometimes go unused because they can be difficult to administer and have bothersome or painful side effects, including flulike symptoms and pain at the site of injection.
February 17, 2011 |
Warm weather is known to aggravate multiple sclerosis, increasing the number of lesions that develop in the brain and spinal cord and leading to a flare-up of symptoms such as numbness and fatigue. But a new study shows that warm weather can also impair cognitive function. The study, which will be presented in April at the annual meeting of the American Academy of Neurology , examined 40 people with the disease and 40 healthy people. The researchers, from the Kessler Foundation in West Orange, N.J., found that people with multiple sclerosis scored 70% better on thinking tests during cooler days as compared with warmer days.
April 13, 2011 |
In the world of “promising” multiple sclerosis drugs, it’s been quite a week. Two more experimental drugs -- both in pill form, not injected -- are joining the race of new treatments to slow the disease. A study of multiple sclerosis patients who took the drug laquinimod over two years had 23% fewer relapses -- an attack of new symptoms or worsening of old ones -- compared with patients who took a sugar pill. The group that received the drug also had a 36% reduction in disability progression and a 33% reduction in brain atrophy.
June 18, 2012 |
Jack Osbourne, son of Sharon and Ozzy Osbourne and a new father as of April, has been diagnosed with multiple sclerosis. And he has a new angle on life as well. "'Adapt and overcome' is my new motto," the reality TV personality told Hello magazine in an interview published Monday. "Thank you all so much for the kind and inspirational words," Osbourne tweeted late Sunday night. "It means a lot. #adaptandovercome . " Suffering vision problems in one eye, Osbourne went for tests just three weeks after daughter Pearl was born, he told the British mag. Optic neuritis is frequently a first symptom of MS, an incurable autoimmune disease that affects the brain and spinal cord and results in an array of symptoms that can range from mild numbness to severe disability.
November 1, 2010 |
Any kid can tell you that Wii games are fun, but people with multiple sclerosis also may find them therapeutic. Wii's motion-sensitive electronic games show some promise in rehabilitating adults with MS, according to British physiotherapist Colin Green. "I have used the Wii system with various clients with MS with some success, in particular in the three areas of balance, aerobic fitness and co-ordination," he writes. Check out the full story at "Does Wii-hab work?" But the medical world has its own devices and "games" that allow MS patients to exercise their arms and legs in hopes that the brain will relearn those actions through repetitive motions.
July 20, 2011 |
It's not enough to bring a new medication to market -- the cost-effectiveness of the drug must be considered as well. A study finds there is a high price for some drugs used to treat the symptoms of multiple sclerosis compared with medications that treat other chronic diseases. The study, released Wednesday online in the journal Neurology , looked at statistics on 844 people over 10 years. The participants had relapsing MS, a common form of the disease. Researchers noted who was taking FDA-approved disease-modifying therapies for MS and also looked at the cost of hospital care and office visits, diagnostic tests, health aides and providers, nursing home care and lost work time.